What is the official website of Evotec BRIDGEs ?

The official website of Evotec BRIDGEs is www.evotec.com.

What is Evotec BRIDGEs's cybersecurity risk score?

Evotec BRIDGEs has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Evotec BRIDGEs experienced?

According to Rankiteo, Evotec BRIDGEs currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Evotec BRIDGEs been affected by any supply chain cyber incidents ?

According to Rankiteo, Evotec BRIDGEs has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Evotec BRIDGEs have SOC 2 Type 1 certification ?

According to Rankiteo, Evotec BRIDGEs is not certified under SOC 2 Type 1.

Does Evotec BRIDGEs have SOC 2 Type 2 certification ?

According to Rankiteo, Evotec BRIDGEs does not hold a SOC 2 Type 2 certification.

Does Evotec BRIDGEs comply with GDPR ?

According to Rankiteo, Evotec BRIDGEs is not listed as GDPR compliant.

Does Evotec BRIDGEs have PCI DSS certification ?

According to Rankiteo, Evotec BRIDGEs does not currently maintain PCI DSS compliance.

Does Evotec BRIDGEs comply with HIPAA ?

According to Rankiteo, Evotec BRIDGEs is not compliant with HIPAA regulations.

Does Evotec BRIDGEs have ISO 27001 certification ?

According to Rankiteo,Evotec BRIDGEs is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Evotec BRIDGEs operate in ?

Evotec BRIDGEs operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Evotec BRIDGEs have ?

Evotec BRIDGEs employs approximately None employees people worldwide.

Does Evotec BRIDGEs own any subsidiaries ?

Evotec BRIDGEs presently has no subsidiaries across any sectors.

How many LinkedIn followers does Evotec BRIDGEs have ?

Evotec BRIDGEs's official LinkedIn profile has approximately 1,191 followers.

What is the NAICS classification code for Evotec BRIDGEs ?

Evotec BRIDGEs is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Evotec BRIDGEs have a Crunchbase profile ?

No, Evotec BRIDGEs does not have a profile on Crunchbase.

Does Evotec BRIDGEs have a LinkedIn profile ?

Yes, Evotec BRIDGEs maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/evotec-bridges.

How many cybersecurity incidents has Evotec BRIDGEs experienced ?

As of September 6, 2026, Rankiteo reports that Evotec BRIDGEs has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Evotec BRIDGEs have ?

Evotec BRIDGEs has an estimated 5,755 peer or competitor companies worldwide.

What types of cybersecurity incidents has Evotec BRIDGEs faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Ransomware and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Evotec BRIDGEs

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Evotec BRIDGEs Vendor Cyber Rating & Cyber Score

evotec.com

Add Your Compliance Badge

A BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) is an integrated fund and award framework to accelerate the translation of early-stage drug discovery from academia to pharma. The goal of our BRIDGE pre-seed partnerships is to unlock the potential of academic innovation from therapeutic concept to investable data point by making our know-how in drug discovery, our technology platforms and matched funding readily available to academic researchers.

Evotec BRIDGEs A.I CyberSecurity Scoring

Scoring History

Evotec BRIDGEs

Evotec BRIDGEs CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Evotec

Ransomware

100

6/2023

EVOEIS177559438...

Evotec BRIDGEs

Cyber Attack

04/2023

EVO133130723

Loading…

A.I.

Evotec BRIDGEs Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Evotec BRIDGEs

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Evotec BRIDGEs in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Evotec BRIDGEs in 2026.

Incident Types Evotec BRIDGEs vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Evotec BRIDGEs in 2026.

Incident History - Evotec BRIDGEs (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Evotec BRIDGEs Subsidiaries

Evotec BRIDGEs

Pharmaceutical Manufacturing

Website: www.evotec.com

Company Size: None employees

EvotecBiotechnology Research

Just - Evotec BiologicsBiotechnology Research

CyprotexResearch Services

PanHunter by EvotecArzneimittelherstellung

Evotec-INDiGOArzneimittelherstellung

Loading…

Evotec BRIDGEs Similar Companies

EMS

cb ems.com.br

Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Loading…

NEWS

Evotec BRIDGEs CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'

Dr Khoo Shih, Chief Executive Officer, ClavystBio, said: "65LAB unites private and public sector players in a shared vision. ClavystBio's ...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-86150

SUMMARY

A security vulnerability has been detected in Tenda CP3 27.5.57.101. Impacted is an unknown function of the file custom-x/softap/hostapd. Such manipulation of the argument wpa_passphrase leads to hard-coded credentials. The attack can be launched remotely. The exploit has been disclosed publicly and may be used.

Published

Date2026-09-05

Updated

Date2026-09-05

RISK INFORMATION (Score: 4.1)

cvss2

Base Score: 3.3

Complexity: LOW

AV:N/AC:L/Au:M/C:P/I:N/A:N

cvss3

Base Score: 4.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:L/I:N/A:N

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:L/VI:N/VA:N/SC:L/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.3

REFERENCES

CVE-2026-86149

SUMMARY

A weakness has been identified in Tenda CP3 27.5.57.101. This issue affects some unknown processing of the file Net/NetCheckPing.cpp. This manipulation of the argument interface_name/host causes os command injection. The attack can be initiated remotely.

Published

Date2026-09-05

Updated

Date2026-09-05

RISK INFORMATION (Score: 9.1)

cvss2

Base Score: 8.3

Complexity: LOW

AV:N/AC:L/Au:M/C:C/I:C/A:C

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 9.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

2.3

REFERENCES

CVE-2026-86148

SUMMARY

A security flaw has been discovered in Tenda CP3 27.5.57.101. This vulnerability affects the function SystemAsh of the file Apis/system.c of the component Kylin. The manipulation of the argument AlarmVoiceURL results in os command injection. It is possible to launch the attack remotely.

Published

Date2026-09-05

Updated

Date2026-09-05

RISK INFORMATION (Score: 9.1)

cvss2

Base Score: 8.3

Complexity: LOW

AV:N/AC:L/Au:M/C:C/I:C/A:C

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 9.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

2.3

REFERENCES

CVE-2026-86206

SUMMARY

A vulnerability in the N-central internal API access control filter allows unauthorised access to internal APIs. This is fixed in N-central 2026.3 HF3 and 2026.4

Published

Date2026-09-05

Updated

Date2026-09-05

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-86060

SUMMARY

RouterOS contains an argument-handling flaw in the SSH login path involving usernames that begin with a prohibited character, allowing for the trusted RouterOS policy mask to be changed, leading to privilege escalation. Exploitation requires an unauthenticated SSH session to reach the RouterOS login helper.This issue was fixed in versions: 6.49.21 (Long-term), 7.23.4 (Long-term) and 7.24.2 (Stable)

Published

Date2026-09-05

Updated

Date2026-09-05

RISK INFORMATION (Score: )

cvss4

Base Score: 9.2

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…